Prototype biomarker data for recurrent Clostridium difficile infections to encompass patient microbiome outcomes data from both microbiota-based therapies
Download this press release (327 KB).
ROSEVILLE, MN – October 22, 2018 — Rebiotix Inc, a clinical-stage biotechnology part of the Ferring Pharmaceuticals Group, announced today that an expanded microbiome analysis using the proprietary MICROBIOME HEALTH INDEX™ will be presented as an oral abstract at the annual United European Gastroenterology (UEG) Conference in Vienna, Austria.
The MICROBIOME HEALTH INDEX™ is under development as a unidimensional metric to assess the extent in which a patient’s microbiome is restored after receiving a microbiota-based therapy; currently, the company is testing an enema formulation known as RBX2660 and a non-frozen, room temperature stable oral formulation, known as RBX7455 in clinical trials to prevent recurrence of Clostridium difficile infection. The team will present data collected from patients pre- and post-treatment from three clinical trials of RBX2660 or RBX7455.
“Even in the prototype stage, the MHI has provided invaluable insight as to how RBX2660 and RBX7455 restore patient microbiomes compared to the pre-treatment state,” said Dr. Ken Blount, Rebiotix Chief Scientific Officer and presenting author of the study. “We are excited to share our findings with our colleagues in hopes that our collective understanding of how the microbiome shapes health or indicates disease can be expanded. Although the MHI is in the early stages, its potential is enormous.”
Dr. Blount’s presentation, titled “Developing Microbiome Restoration Biomarkers for Clostridium difficile Infections: Continued Evaluation of a Prototype MICROBIOME HEALTH INDEX™,” will take place on Tuesday, October 23 during the 10:30 AM session (OP177) in Room K of Austria Center Vienna.
About Rebiotix Inc.
Rebiotix Inc, part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection. RBX2660 has been granted Fast Track, Orphan and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff infection. Rebiotix’s clinical pipeline also features RBX7455, a lyophilized, room temperature stable oral capsule formulation. Rebiotix is also targeting several other disease states with drug products built on its pioneering Microbiota Restoration Therapy™ platform. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalized healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
Rebiotix Media Contact: